Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
Name
s41467-017-02294-6.pdf
Size
1.26 MB
Format
Adobe PDF
Checksum (MD5)
0eda897b00fe36b8dfce324dc5bce844
Author(s)
Hill, Alison L.
Selinger, Christian
Bershteyn, Anna
Craig, Morgan
Mo, Shirley S.
Nikolic, Boris
Wood, Lowell
Eckhoff, Philip A.
Nowak, Martin A.
Kirtane, Ameya
Date Issued
January 2018
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Kirtane, Ameya R. et al. “Development of an Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy.” Nature Communications 9, 1 (January 2018): 2 © 2017 The Author(s)
Version
Final published version
Abstract
The efficacy of antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug-polymer matrices which achieved week-long systemic drug levels of the antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Massachusetts Institute of Technology. Media Laboratory
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Attribution 4.0 International (CC BY 4.0)
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41467-017-02294-6
